“…Although ideal treatment remains unclear, therapeutic options include topical, intralesional, and systemic corticosteroids, as well as cryotherapy, topical and oral retinoids, topical calcineurin inhibitors, tetracyclines, dapsone, antimalarials, adalimumab, immunosuppressants, and laser therapy. 4,7,[11][12][13][14][15][16][17][18][19][20][21] While hydroxychloroquine has demonstrated efficacy in treating actinic granuloma in numerous reports; the patient described herein refused hydroxychloroquine treatment due to apprehension regarding adverse effects based on her perception of negative media coverage of the medication during the COVID-19 pandemic. 4,[19][20][21] While concern for hydroxychloroquine shortages was reported in the rheumatologic literature early in the pandemic, little is written about sensationalism associated with hydroxychloroquine during the COVID-19 pandemic and its potential to affect patients' future decision-making with respect to treatment with this drug for rheumatologic and dermatologic conditions.…”